ImmunityBio [IBRX] vs Regeneron [REGN] Detailed Stock Comparison
ImmunityBio
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: ImmunityBio wins in 10 metrics, Regeneron wins in 8 metrics, with 0 ties. ImmunityBio appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ImmunityBio | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -3.86 | 14.95 | ImmunityBio |
| Price-to-Book Ratio | -3.55 | 2.06 | ImmunityBio |
| Debt-to-Equity Ratio | -1.48 | 9.04 | ImmunityBio |
| PEG Ratio | 0.08 | 13.09 | ImmunityBio |
| EV/EBITDA | -11.52 | 12.21 | ImmunityBio |
| Profit Margin (TTM) | 100.00% | 31.37% | ImmunityBio |
| Operating Margin (TTM) | -269.76% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | 84.72% | 15.34% | ImmunityBio |
| Return on Assets (TTM) | -42.14% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-398.12M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -45.65% | -50.84% | ImmunityBio |
| Price-to-Sales Ratio (TTM) | 40.58 | 4.42 | Regeneron |
| Enterprise Value | $3.10B | $54.52B | Regeneron |
| EV/Revenue Ratio | 54.78 | 3.84 | Regeneron |
| Gross Profit Margin (TTM) | 99.49% | 85.58% | ImmunityBio |
| Revenue per Share (TTM) | $0 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-0.48 | $39.68 | Regeneron |
| Beta (Stock Volatility) | -0.07 | 0.33 | ImmunityBio |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
ImmunityBio vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ImmunityBio | 3.12% | -9.41% | -14.76% | -13.81% | -28.26% | -10.12% |
| Regeneron | -1.45% | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ImmunityBio | -45.65% | -43.52% | -68.40% | -87.55% | -92.45% | -92.45% |
| Regeneron | -50.84% | -1.12% | -2.18% | 9.83% | 2,487.71% | 7,770.23% |
Performance & Financial Health Analysis: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $2.30B | $62.88B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 10,151,771 | 859,422 |
| 90 Day Avg. Volume | 8,537,560 | 933,271 |
| Last Close | $2.31 | $589.48 |
| 52 Week Range | $1.83 - $7.48 | $476.49 - $1,211.20 |
| % from 52W High | -69.12% | -51.33% |
| All-Time High | $45.42 (Feb 22, 2021) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -94.91% | -51.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 24.24% | 0.04% |
| Quarterly Earnings Growth | 24.24% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 1.00% | 0.31% |
| Operating Margin (TTM) | -2.70% | 0.30% |
| Return on Equity (TTM) | 0.85% | 0.15% |
| Debt to Equity (MRQ) | -1.48 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.62 | $287.55 |
| Cash per Share (MRQ) | $0.16 | $72.04 |
| Operating Cash Flow (TTM) | $-349,558,016 | $4.74B |
| Levered Free Cash Flow (TTM) | $-249,235,872 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -3.86 | 14.95 |
| Forward P/E | -3.86 | 13.09 |
| PEG Ratio | 0.08 | 13.09 |
| Price to Sales (TTM) | 40.58 | 4.42 |
| Price to Book (MRQ) | -3.55 | 2.06 |
| Market Capitalization | ||
| Market Capitalization | $2.30B | $62.88B |
| Enterprise Value | $3.10B | $54.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 54.78 | 3.84 |
| Enterprise to EBITDA | -11.52 | 12.21 |
| Risk & Other Metrics | ||
| Beta | -0.07 | 0.33 |
| Book Value per Share (MRQ) | $-0.62 | $287.55 |
Financial Statements Comparison: ImmunityBio vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Revenue/Sales | $16.52M | $3.03B |
| Cost of Goods Sold | $58,000 | $464.30M |
| Gross Profit | $16.46M | $2.56B |
| Research & Development | $48.23M | $1.34B |
| Operating Income (EBIT) | $-64.43M | $591.70M |
| EBITDA | $-102.70M | $900.90M |
| Pre-Tax Income | $-129.90M | $905.00M |
| Income Tax | $-234,000 | $96.30M |
| Net Income (Profit) | $-129.67M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Cash & Equivalents | $60.66M | $3.09B |
| Total Current Assets | $109.16M | $17.57B |
| Total Current Liabilities | $49.21M | $3.57B |
| Long-Term Debt | $518.81M | $2.70B |
| Total Shareholders Equity | $-590.48M | $29.39B |
| Retained Earnings | $-3.50B | $32.38B |
| Property, Plant & Equipment | $106.70M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IBRX | REGN |
|---|---|---|
| Operating Cash Flow | $-35.91M | $1.36B |
| Capital Expenditures | $-1.08M | N/A |
| Free Cash Flow | $-80.83M | $773.60M |
| Debt Repayment | $-4,000 | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | IBRX | REGN |
|---|---|---|
| Shares Short | 77.07M | 2.29M |
| Short Ratio | 10.42 | 2.55 |
| Short % of Float | 0.26% | 0.02% |
| Average Daily Volume (10 Day) | 10,151,771 | 859,422 |
| Average Daily Volume (90 Day) | 8,537,560 | 933,271 |
| Shares Outstanding | 852.90M | 109.62M |
| Float Shares | 193.56M | 97.89M |
| % Held by Insiders | 0.69% | 0.02% |
| % Held by Institutions | 0.13% | 0.91% |
Dividend Analysis & Yield Comparison: ImmunityBio vs Regeneron
| Metric | IBRX | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |